Literature DB >> 29577557

Myeloperoxidase, superoxide dismutase-3, cardiometabolic risk factors, and distal sensorimotor polyneuropathy: The KORA F4/FF4 study.

Christian Herder1,2, Julia M Kannenberg1,2, Cornelia Huth2,3, Maren Carstensen-Kirberg1,2, Wolfgang Rathmann2,4, Wolfgang Koenig5,6, Alexander Strom1,2, Gidon J Bönhof1, Margit Heier3, Barbara Thorand2,3, Annette Peters2,3, Michael Roden1,2,7, Christa Meisinger2,3,8, Dan Ziegler1,2,7.   

Abstract

BACKGROUND: Oxidative stress has been proposed as important pathomechanism of cardiometabolic diseases and distal sensorimotor polyneuropathy (DSPN). However, the relevance of biomarkers of oxidative stress has not been investigated in this context. Therefore, this study aimed to assess the association of the prooxidant myeloperoxidase (MPO) and the antioxidant extracellular superoxide dismutase (SOD3) with cardiometabolic risk factors and with prevalence and incidence of DSPN.
METHODS: Cross-sectional analyses comprised 1069 participants (40.3% with prediabetes and 20.5% with type 2 diabetes) of the population-based Cooperative Health Research in the Region of Augsburg (KORA) F4 study (2006-2008), 181 of whom had DSPN at baseline. Prospective analyses included 524 individuals without DSPN at baseline who also participated in the KORA FF4 study (2013-2014), 132 of whom developed DSPN during the 6.5-year follow-up. Serum MPO and SOD3 were measured by ELISA, and their association with cardiometabolic risk factors and DSPN were estimated by using linear and logistic regression analyses.
RESULTS: Higher MPO and SOD levels showed multiple positive associations with cardiometabolic risk factors including age, indices of obesity, insulin resistance, serum lipids, renal dysfunction, and biomarkers of inflammation. Higher MPO levels were associated with prevalent DSPN (fully adjusted OR 1.38 [95% CI 1.10; 1.72] per doubling of MPO). Higher baseline SOD3 levels were related to incident DSPN (age and sex-adjusted OR 2.14 [1.02; 4.48] per doubling of SOD3), which was partially explained by cardiometabolic risk factors.
CONCLUSIONS: Systemic levels of both pro- and antioxidant enzymes appear involved in cardiometabolic risk and development of DSPN.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cardiovascular risk factors; myeloperoxidase; neuropathy; oxidative stress; polyneuropathy; superoxide dismutase

Mesh:

Substances:

Year:  2018        PMID: 29577557     DOI: 10.1002/dmrr.3000

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  7 in total

Review 1.  Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy.

Authors:  Gordon Sloan; Dinesh Selvarajah; Solomon Tesfaye
Journal:  Nat Rev Endocrinol       Date:  2021-05-28       Impact factor: 43.330

2.  Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial.

Authors:  Theresia Sarabhai; Lucia Mastrototaro; Sabine Kahl; Gidon J Bönhof; Marc Jonuscheit; Pavel Bobrov; Hisayuki Katsuyama; Rainer Guthoff; Martin Wolkersdorfer; Christian Herder; Sven G Meuth; Sven Dreyer; Michael Roden
Journal:  Diabetologia       Date:  2022-09-30       Impact factor: 10.460

3.  Association of C-Terminal Pro-Endothelin-1 with Mortality in the Population-Based KORA F4 Study.

Authors:  Cornelia Then; Chaterina Sujana; Christian Herder; Holger Then; Margit Heier; Christa Meisinger; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Haifa Maalmi; Katrin Ritzel; Michael Roden; Michael Stumvoll; Barbara Thorand; Jochen Seissler
Journal:  Vasc Health Risk Manag       Date:  2022-05-03

4.  Association of circulating MR-proADM with all-cause and cardiovascular mortality in the general population: Results from the KORA F4 cohort study.

Authors:  Christina Gar; Barbara Thorand; Christian Herder; Chaterina Sujana; Margit Heier; Christa Meisinger; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Michael Roden; Michael Stumvoll; Haifa Maalmi; Thomas Meitinger; Holger Then; Jochen Seissler; Cornelia Then
Journal:  PLoS One       Date:  2022-01-06       Impact factor: 3.240

5.  Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes.

Authors:  Noo Ree Cho; Yeuni Yu; Chang-Kyu Oh; Dai Sik Ko; Kyungjae Myung; Yoonsung Lee; Hee Sam Na; Yun Hak Kim
Journal:  Ther Adv Chronic Dis       Date:  2021-09-08       Impact factor: 5.091

6.  Plasma 1,5-anhydro-D-glucitol is associated with peripheral nerve function and diabetic peripheral neuropathy in patients with type 2 diabetes and mild-to-moderate hyperglycemia.

Authors:  Feng Xu; Li-Hua Zhao; Xiao-Hua Wang; Chun-Hua Wang; Chao Yu; Xiu-Lin Zhang; Li-Yan Ning; Hai-Yan Huang; Jian-Bin Su; Xue-Qin Wang
Journal:  Diabetol Metab Syndr       Date:  2022-01-29       Impact factor: 3.320

7.  Serum uromodulin is inversely associated with biomarkers of subclinical inflammation in the population-based KORA F4 study.

Authors:  Cornelia Then; Christian Herder; Holger Then; Barbara Thorand; Cornelia Huth; Margit Heier; Christa Meisinger; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Michael Roden; Michael Stumvoll; Haifa Maalmi; Thomas Meitinger; Andreas Lechner; Jürgen Scherberich; Jochen Seissler
Journal:  Clin Kidney J       Date:  2020-09-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.